Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 13, 2022

CDK 4/6 Inhibitor Ribociclib in Combination With Docetaxel Plus Prednisone in mCRPC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A phase Ib/II study of the CDK 4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration-resistant prostate cancer
Clin. Cancer Res 2022 Feb 17;[EPub Ahead of Print], I de Kouchkovsky, A Rao, BA Carneiro, L Zhang, C Lewis, A Phone, EJ Small, T Friedlander, L Fong, PL Paris, CJ Ryan, RZ Szmulewitz, R Aggarwal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading